

Oncology Clinical Pathways

Meningioma

July 2024 – V1.2024



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Table of Contents

| | |
|---|---|
| Presumptive Conditions | 3 |
| Initial Evaluation | 4 |
| Molecular Testing Table | 5 |



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Meningioma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Atomic Veterans Exposed to Ionizing Radiation

- Brain Cancer

Gulf War and Post 9/11 Veterans


If the patient served on or after Sept. 11, 2001, in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen or if you served in the *Southwest Asia theater of operations, or Somalia, on or after Aug. 2, 1990, specific conditions include:

- Brain Cancer

* The Southwest Asia theater of operations refers to Iraq, Kuwait, Saudi Arabia, the neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above these locations.

For more information, please visit [U.S. Department of Veterans Affairs - Presumptive Disability Benefits \(va.gov\)](https://www.va.gov)

Meningioma – Initial Evaluation



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

- ^a **Imaging** MRI with and without contrast; CT with contrast if MRI contraindicated; needs evaluation for hereditary syndromes including neurofibromatosis type 2 with referral to Genetics
 - ^b **Patient** is symptomatic and/or MRI interval changes
 - ^c **Surveillance** changes in tumor size or symptoms require multidisciplinary discussion through local tumor board or National TeleOncology CNS Virtual Tumor Board
 - ^d **Simpson Grades** 1 through 3 indicate gross total resection; grades 4 and 5 indicate subtotal resection
 - ^e **Timing of Post-Resection MRI** per neurosurgeon discretion
 - ^f **Refer to Neuro-oncology** via National TeleOncology consult if local VA Neuro-oncology unavailable
 - ^g **Confirmed** by pathology with TERT mutation testing and FISH for CDKN2A/CDKN2B; Neuropathology consult should be requested for morphologically challenging cases
 - ^h **Interval** may increase after 5 years without tumor recurrence
- WHO World Health Organization

Meningioma – Molecular Testing Table

| | | | | | |
|-------------|-----------------------|--------------------------------|---------------------------------------|----|---------------------|
| Meningiomas | FISH | CDKN2A/B homozygous loss | Local VA or locally contracted vendor | No | Tumor Tissue, Blood |
| | Molecular Testing | TERT promoter mutation testing | Local VA or locally contracted vendor | No | Tumor Tissue |
| | Molecular/Cytogenetic | Chromosomal microarray | Local VA or locally contracted vendor | No | Tumor Tissue |

